Cromatina/Epigenética
Os inibidores de cromatina/epigenética são compostos que modulam a estrutura e função da cromatina ou interferem em modificações epigenéticas, como a metilação do DNA e a modificação de histonas. Esses inibidores são ferramentas essenciais para estudar a regulação da expressão gênica e o papel da epigenética em doenças como o câncer, distúrbios neurológicos e anomalias do desenvolvimento. Ao direcionar os processos epigenéticos, esses inibidores podem alterar os padrões de expressão gênica e oferecer novas vias terapêuticas. Na CymitQuimica, oferecemos uma ampla seleção de inibidores de cromatina/epigenética de alta qualidade para apoiar sua pesquisa em biologia molecular, genética e epigenética.
Subcategorias de "Cromatina/Epigenética"
Foram encontrados 2252 produtos de "Cromatina/Epigenética"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
CAY10685
CAS:<p>CAY10685, a CPTH2 analog with an alkyne for click reactions, inhibits NAT10 to study cancer-related chromatin changes.</p>Fórmula:C17H16ClN3SCor e Forma:SolidPeso molecular:329.85BRD4 Inhibitor-25
<p>BRD4 Inhibitor-25 blocks BRD4 (BD1: IC50 0.82 μM, BD2: 1.94 μM), induces cell death in ovarian cancer, used in cancer research.</p>Fórmula:C29H27N5O6SCor e Forma:SolidPeso molecular:573.62J1038
CAS:<p>J1038 is a novel Histone Deacetylase 8 (HDAC8) Inhibitor .</p>Fórmula:C10H10N2O3SCor e Forma:SolidPeso molecular:238.26HDAC8/BRPF1-IN-1
CAS:<p>Compound 23a, dual HDAC8/BRPF1 inhibitor: IC50 HDAC8 = 443 nM, Kd BRPF1 = 67 nM; weak against HDAC1/6.</p>Fórmula:C19H19N3O6SCor e Forma:SolidPeso molecular:417.44HDAC6-IN-14
<p>HDAC6-IN-14, an inhibitor of HDAC6 (HDAC), exhibits high selectivity with an IC50 value of 42 nM, demonstrating over 100-fold selectivity compared to HDAC1,</p>Fórmula:C24H30FN3O4Cor e Forma:SolidPeso molecular:443.51BI-831266
CAS:<p>BI-831266 is a potent and selective Aurora kinase B inhibitor.</p>Fórmula:C27H38ClN7O2Cor e Forma:SolidPeso molecular:528.09HDAC-IN-41
CAS:<p>HDAC-IN-41 is a selective class I HDAC inhibiting HDAC1, 2, & 3 with IC50: 0.62-1.46 µM; oral use; has NO-release.</p>Fórmula:C20H22N4O6SCor e Forma:SolidPeso molecular:446.48PARP11 inhibitor ITK7
CAS:<p>ITK7 is a potent, selective PARP11 inhibitor with an IC50 of 14 nM, useful for cellular localization research.</p>Fórmula:C17H14N4OSCor e Forma:SolidPeso molecular:322.38PIM1-IN-6
CAS:<p>PIM1-IN-6 (5h) inhibits PIM-1 (IC50: 0.60 μM) and is cytotoxic to HCT-116 (IC50: 1.51 μM) and MCF-7 cells (IC50: 15.2 μM).</p>Fórmula:C21H18N6O4Cor e Forma:SolidPeso molecular:418.41HDAC1/MAO-B-IN-1
CAS:<p>HDAC1/MAO-B-IN-1 is a selective Alzheimer’s research inhibitor with IC50s: HDAC1 (21.4 nM) & MAO-B (99 nM); crosses the blood-brain barrier.</p>Fórmula:C18H17ClN2O2Cor e Forma:SolidPeso molecular:328.79Aurora kinase inhibitor-9
CAS:<p>Aurora kinase inhibitor-9 (9d) targets AURKA/B with IC50: 0.093 μM for A and 0.09 μM for B, with wide anti-proliferative effects.</p>Fórmula:C19H17Cl2N3O4SCor e Forma:SolidPeso molecular:454.33BET-IN-7
CAS:<p>BET-IN-7 is a potent BET inhibitor with a Ki of 12.27 μM and Kd of 89.3 μM, useful in sepsis research.</p>Fórmula:C18H12ClN3OSCor e Forma:SolidPeso molecular:353.83SGC6870
CAS:<p>SGC6870 is a novel potent, selective, and cell-active inhibitor of PRMT6 with IC50 of 77 ± 6 nM, being selective over all other PRMTs and 23 methyltransferases.</p>Fórmula:C23H21BrN2O2SCor e Forma:SolidPeso molecular:469.39DCE_42
CAS:<p>DCE_42 is a novel EZH2 inhibitor, it also displays significant anti-proliferation activity against lymphoma cell lines.</p>Fórmula:C22H19N9O2SPureza:98%Cor e Forma:SolidPeso molecular:473.51Tankyrase-IN-4
<p>Tankyrase-IN-4 is a potent inhibitor of tankyrase 1 (TNKS1), exhibiting an IC50 of 0.8 nM, and is utilized in cancer research.</p>Fórmula:C25H24N6O5Cor e Forma:SolidPeso molecular:488.5OUL245
CAS:<p>OUL245: A selective PARP2 inhibitor (IC50=44nM), also inhibits other PARPs/TNKS (IC50=2.9-8.8μM).</p>Fórmula:C8H5N3OSCor e Forma:SolidPeso molecular:191.21HDAC6-IN-15
<p>HDAC6-IN-15: selective HDAC6 inhibitor, IC50 of 38.2 nM, for cancer and neurodegenerative research.</p>Fórmula:C25H28FFeN3O2Cor e Forma:SolidPeso molecular:477.35DS-437
CAS:<p>DS-437 is a dual PRMT5/7 inhibitor (IC50s: 6 μM). DS-437 also inhibits DNMT3A and DNMT3B (IC50s: 52 and 62 μM). DS-437 inhibits the methylation of FOXP3.</p>Fórmula:C15H23N7O4SPureza:98%Cor e Forma:SolidPeso molecular:397.45CYP51/HDAC-IN-1
CAS:<p>Orally active CYP51/HDAC-IN-1 dual inhibitor targets virulence factors and resistance genes; effective against Candidiasis and Cryptococcal meningitis.</p>Fórmula:C30H40F2N6O4Cor e Forma:SolidPeso molecular:586.67CBB1003
CAS:<p>CBB1003 is a new inhibitor of histone demethylase LSD1 (IC50: 10.54 μM).</p>Fórmula:C25H31N9O4Pureza:98%Cor e Forma:SolidPeso molecular:521.57KBH-A42
CAS:<p>KBH-A42 is an inhibitor of histone deacetylase.</p>Fórmula:C17H22N2O3Pureza:98%Cor e Forma:SolidPeso molecular:302.37PKN1/2-IN-1
CAS:<p>PKN1/2-IN-1 is a potent and selective PKN2 inhibitor, membrane permeability and anticancer.Protein kinase N proteins (PKN) are effectors of Rho GTPases.</p>Fórmula:C14H15N3OPureza:99.72%Cor e Forma:SolidPeso molecular:241.29MI-1
CAS:<p>MI-1 inhibits Menin-MLL interaction with an IC 50 of 1.9 μM [1].</p>Fórmula:C19H25N5S2Cor e Forma:SolidPeso molecular:387.57Piribedil dihydrochloride
CAS:<p>dopamine agonist</p>Fórmula:C16H20Cl2N4O2Pureza:98%Cor e Forma:SolidPeso molecular:371.26Dot1L-IN-7
CAS:<p>Dot1L-IN-7 (compound 25), a potent DOT1L inhibitor with an IC50 of 1.0 μM, selectively kills MLL-AF9, sparing E2A-HLF cells.</p>Fórmula:C23H27N9O2Cor e Forma:SolidPeso molecular:461.52HDAC-IN-28
CAS:<p>HDAC-IN-28 is a novel inhibitor of HDAC that significantly inhibits tumour growth and metastasis.</p>Fórmula:C23H26N4O4SCor e Forma:SolidPeso molecular:454.54Y08175
CAS:<p>Y08175, a CBP Bromodomain inhibitor, IC50: 37 nM (AlphaScreen), 178.15 nM (HTRF). Useful in prostate cancer research.</p>Fórmula:C23H19FN4O5Cor e Forma:SolidPeso molecular:450.426-Methyl-5-azacytidine
CAS:<p>6-Methyl-5-azacytidine is a potent DNMT inhibitor.</p>Fórmula:C9H14N4O5Pureza:98%Cor e Forma:SolidPeso molecular:258.23CEP-8983
CAS:<p>CEP-8983 is a PARP inhibitor potentially for the treatment of solid tumours.</p>Fórmula:C18H14N2O3Pureza:98%Cor e Forma:SolidPeso molecular:306.32JS1310
CAS:<p>JS1310 is a selective PRMT7 inhibitor (IC50: 5 μM against human PRMT7). JS1310 has shown anti-cancer effects on different cancer cells.</p>Fórmula:C23H22FN5O3Cor e Forma:SolidPeso molecular:435.45ARTD10/PARP10-IN-2
CAS:<p>ARTD10/PARP10-IN-2: A potent, non-selective PARP inhibitor, IC50: ARTD10/PARP10 (2.0μM), ARTD1/PARP1 (9.7μM).</p>Fórmula:C12H13N3O3Cor e Forma:SolidPeso molecular:247.25OHM1
CAS:<p>OHM1, an analog of HIF1α CTAD, effectively inhibits the interaction between HIF1α CTAD and p300/CBP by targeting the CH1 domain with a binding affinity of 0.53</p>Fórmula:C24H42N6O5Cor e Forma:SolidPeso molecular:494.63PARP1-IN-11
CAS:PARP1-IN-11 is a potent PARP1 inhibitor (IC50=0.082 μM), also reducing PARP3, TNKS1, and TNKS2 activity.Fórmula:C16H12N2O4Cor e Forma:SolidPeso molecular:296.28SDR-04
CAS:<p>SDR-04 inhibits BRD4-BD1 with high affinity, suppressing MV4;11 cancer cell growth as a BET inhibitor.</p>Fórmula:C19H16N4O2Cor e Forma:SolidPeso molecular:332.36CP-690550A
CAS:<p>Cp-690550a is a novel JAK3 inhibitor, which is used to treat rheumatoid arthritis, graft rejection, psoriasis, and other immune-mediated diseases.</p>Fórmula:C15H21N5O2Cor e Forma:SolidPeso molecular:303.36ABT-472
CAS:<p>ABT-472 is a novel PARP inhibitor</p>Fórmula:C20H28N4O5Cor e Forma:SolidPeso molecular:404.46CBHA
CAS:<p>m-Carboxycinnamic bishydroxamide: HDAC inhibitor, ID50 = 10 nM (HDAC1), 70 nM (HDAC3), induces apoptosis and tumor growth suppression.</p>Fórmula:C10H10N2O4Cor e Forma:SolidPeso molecular:222.2PI3K/HDAC-IN-1
CAS:<p>PI3K/HDAC-IN-1 is a potent PI3K and HDAC dual inhibitor(IC50s of 8.1 nM and 1.4 nM, respectively).</p>Fórmula:C22H25FN4O4Pureza:98%Cor e Forma:SolidPeso molecular:428.46BRD4-BD1-IN-1
CAS:<p>BRD4-BD1-IN-1 (Compound 9a) is a BRD4-BD1 inhibitor(IC50= 38.20 μM).</p>Fórmula:C16H15BrN4O4Cor e Forma:SolidPeso molecular:407.22TP-238
CAS:<p>"TP-238: Potent CECR2/BPTF dual probe; IC50: 30 nM/350 nM. Inhibits BRD9 (pIC50: 5.9); minimal activity on 338 other kinases."</p>Fórmula:C22H30N6O3SCor e Forma:SolidPeso molecular:458.58BRD4 Inhibitor-19
CAS:<p>BRD4 inhibitors -19 are BET inhibitors that act on BRD4-BD1 (IC50: 55 nM) and can be used to study multiple myeloma.</p>Fórmula:C29H25N5O3Cor e Forma:SolidPeso molecular:491.54JAK-STAT-IN-1
CAS:<p>JAK-STAT-IN-1 is a specific JAK-STAT inhibitor indicated for the study of autoimmune diseases.</p>Fórmula:C21H21N5O2Pureza:99.59%Cor e Forma:SolidPeso molecular:375.42BRD4 Inhibitor-20
CAS:<p>BRD4 Inhibitor-20 is a potent bromodomain protein 4 (BRD4) inhibitor with oral activity.</p>Fórmula:C18H18N2O4SPureza:99.84%Cor e Forma:SolidPeso molecular:358.41TM2-115
CAS:<p>TM2-115 is a inhibitor of malaria parasite histone methyltransferases that results in rapid and irreversible parasite death [1].</p>Fórmula:C28H38N6O2Pureza:97.67%Cor e Forma:SolidPeso molecular:490.64PU139
CAS:<p>PU139 is a novel inhibitor of histone acetyltransferase (HAT).</p>Fórmula:C12H7FN2OSPureza:99.96%Cor e Forma:SolidPeso molecular:246.26CD532
CAS:<p>CD532: Potent Aurora A inhibitor, IC50=45 nM, blocks kinase activity, degrades MYCN, interacts with AURKA, studies cancer.</p>Fórmula:C26H25F3N8OPureza:99.49%Cor e Forma:SolidPeso molecular:522.52CEP-9722
CAS:<p>CEP-9722 is a PARP-1 and PARP-2 inhibitor with anticancer activity and is used in the study of ovarian cancer.</p>Fórmula:C24H26N4O3Pureza:98.38% - 98.56%Cor e Forma:SolidPeso molecular:418.49SK-575
CAS:SK-575 is a potent PARP1-degrading agent effective against BRCA1/2 mutant cancers, even at low doses, and enhances tumor inhibition in mice.Fórmula:C47H53FN8O8Pureza:99.39%Cor e Forma:SolidPeso molecular:876.97MS0124
CAS:<p>MS0124 is a potent and selective G9A-like protein (GLP) inhibitor with IC50 values of 13±4 nM and 440±63 nM, respectively.</p>Fórmula:C20H29N5O3Pureza:98.97%Cor e Forma:SolidPeso molecular:387.48ML192
CAS:<p>ML192 (CID1434953) is a selective GPR55 ligand antagonist.</p>Fórmula:C20H22N4O2SPureza:99.17%Cor e Forma:SolidPeso molecular:382.48
